Company intelligence / Profile preview
Prosidion Ltd.
Oxford, Oxfordshire, United Kingdomprosidion.com ↗
- Ownership
- Private
- Employees
- ~8
- Development stage
- Other
01
Overview
Prosidion Ltd. was a UK-based biopharmaceutical company focused on innovative molecular targeted therapies for type 2 diabetes and obesity. It developed small molecule drugs targeting mechanisms such as GPR119 agonists, DPP-IV inhibitors, and others. The company’s main value came from its intellectual property portfolio around DPP-IV inhibitors for diabetes, which it sold to Royalty Pharma in a $609 million deal in July 2011. Most internal R&D programs were discontinued before the company's dissolution.
- Therapeutic areas
- Endocrinology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
Non-exclusive licenses granted to various pharmaceutical companies worldwide for use of its DPP-IV inhibitor patents.
Beyond the preview
Go deeper on Prosidion Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Prosidion Ltd..